Grifols, S.A.
GRFSNASDAQHealthcareDrug Manufacturers - General
As of Oct 26, 2026 close
- Market cap
- $5.39B
- P/E (TTM)
- 9.90
- Forward P/E
- 6.64
- Dividend yield
- 1.15%
- 52-week range
- $6.96$9.90
- Volume (live)
- -
- Avg. volume (3M)
- 662.51K
Grifols (GRFS) Stock Price & Financial Analysis
Grifols Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $7.76 - $8.11 |
|---|---|
| 52-Week High | $9.90 |
| 52-Week Low | $6.96 |
| Open | $7.76 |
| Volume (last close) | 845.89K |
| Average Volume (3M) | 662.51K |
| Revenue (TTM) | 8.32B |
|---|---|
| Net Income (TTM) | 544.28M |
| Free Cash Flow (TTM) | 803.03M |
| EPS (TTM) | $0.87 |
| Profit Margin | 6.54% |
| Operating Margin | 16.23% |
| Return on Equity (ROE) | 8.79% |
| Debt to Equity | 1.35 |
| Annual Dividend | $0.11 |
|---|---|
| Dividend Yield | 1.15% |
| Payout Ratio | 9.85% |
| Last Dividend Ex-Date | Jul 2, 2026 |
| Market Cap | 5.39B |
|---|---|
| Shares Outstanding | 680.58M |
| P/E Ratio (TTM) | 9.90 |
| Forward P/E | 6.64 |
| Price to Sales (P/S) | 0.65 |
| Price to Book (P/B) | 0.87 |
| EV/EBITDA | 7.38 |
| 50-Day MA | $7.60 |
|---|---|
| 200-Day MA | $8.05 |
| 1-Year Change | −21.99% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Grifols at a Glance
As of the Oct 26, 2026 close, Grifols (GRFS) has a market capitalization of $5.39B. The stock trades at 9.9× trailing earnings, 6.6× forward earnings and 0.7× sales. Over the trailing twelve months it earned $544.28M on revenue of $8.32B (a 6.5% profit margin) and generated $803.03M of free cash flow. Revenue fell 0.3% year over year.
As of its latest reported balance sheet, it holds $572.94M in cash and securities against $8.35B of debt, a net debt position of $7.77B.
Grifols pays dividends totaling $0.11 per share a year, a 1.15% yield at the Oct 26, 2026 close, with a 10% payout ratio.
The share price is down 22.0% over the past year. At $7.92 (the Oct 26, 2026 close) it sits within its 52-week range of $6.96 to $9.90, below its 200-day moving average of $8.05.
Based on 1 professional analyst rating from the past 90 days, the consensus is Buy.
Frequently Asked Questions About Grifols
What is the current stock price for GRFS?
As of the Oct 26, 2026 close, GRFS stock trades at $7.92. The 52-week range is $6.96–$9.90, with a day range of $7.76–$8.11.
What is the P/E ratio for GRFS?
As of the Oct 26, 2026 close, Grifols's trailing twelve-month (TTM) P/E ratio is 9.9, meaning investors pay $9.9 for every $1 of annual earnings. The forward P/E is 6.6, reflecting analyst expectations for future earnings. Grifols operates in the Healthcare sector.
Does GRFS pay dividends?
Yes, Grifols pays a 1.15% annual dividend yield as of the Oct 26, 2026 close ($0.11 per share a year). The trailing twelve-month payout ratio is 9.8%. The most recent ex-dividend date was July 2, 2026.
What do analysts recommend for GRFS?
Based on ratings from 1 professional analyst over the last 90 days, the consensus for GRFS is Buy.
What is the market cap of GRFS?
As of the Oct 26, 2026 close, Grifols's market capitalization is $5.39B, classifying it as a mid-cap company. Grifols operates in the Healthcare sector within the Drug Manufacturers - General industry.